医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NICHIBAN to Establish European Subsidiary “NICHIBAN EUROPE GmbH” in Germany

2020年07月21日 PM02:00
このエントリーをはてなブックマークに追加


 

TOKYO

NICHIBAN CO., LTD., based in Tokyo, announced that it will open a new European subsidiary, “NICHIBAN EUROPE GmbH” in Dusseldorf, Germany, in October 2020.

As part of the expansion of the company’s overseas business, NICHIBAN opened a representative office in Dusseldorf in January 2019 to expand the sales business of its products throughout Europe and promote its business strategy. By establishing a sales subsidiary in Germany, NICHIBAN will work to strengthen business and expand sales in Europe through sales activities that are closely related to local markets.

Outline of the subsidiary

(1) Company name: NICHIBAN EUROPE GmbH
(2) Location: Oststrasse 54 40211 Dusseldorf, NRW, Germany
(3) Date of establishment: October 2020 (provisional)
(4) Description of business: Sales of NICHIBAN products in Europe

About NICHIBAN CO., LTD.

NICHIBAN CO., LTD. (TOKYO:4218) is a leading Japanese adhesive tape manufacturer. Since the founding in 1918, the company has focused on adhesive technology for producing adhesive bandages and surgical tapes for hospitals and pharmacies, as well as stationery such as cellulose tapes and industrial tapes. Production bases are in Japan and Thailand.

Please visit the company’s website for more information at https://www.nichiban.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005230/en/

CONTACT

Masao Miyamoto

Dusseldorf Representative Office

NICHIBAN CO., LTD.

Tel: +49-211-74073140

Email: ibd@nichiban.co.jp

同じカテゴリーの記事 

  • Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)